Camurus ABCAMRF 81 Forward PE Ratio is 38.98 as of Jul. 03, 2026. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $73.90 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 355 Biotechnology companies, Camurus AB ranks worse than 66.2% on this metric.
Camurus AB (OTCPK:CAMRF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Camurus AB Forward PE Ratio Related Terms
Camurus AB Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Camurus AB's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB Forward PE Ratio Chart
Camurus AB Annual Data
Trend
2022-12
2024-12
2025-12
Forward PE Ratio
26.67
30.81
32.15
Camurus AB Quarterly Data
2022-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
26.67
105.26
133.33
34.60
30.81
36.09
42.45
26.26
32.15
31.72
CAMRF vs VRTX, REGN, ALNY: Forward PE Ratio Comparison
For the Biotechnology subindustry, Camurus AB's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Camurus AB's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Camurus AB (CAMRF) has a Forward PE Ratio of 38.98 as of Jul. 03, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #235 out of 355 companies in the Biotechnology industry, placing it in the top 66.2%.
Is Camurus AB's Forward PE Ratio too high?
Camurus AB's current Forward PE Ratio is 38.98. The Biotechnology industry median Forward PE Ratio is 22.47. Camurus AB's value of 38.98 is 73.5% above this industry median. Based on the distribution chart, Camurus AB ranks #235 out of 355 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #235 out of 355 companies for Forward PE Ratio. This places Camurus AB in the lower half of its industry. The industry median Forward PE Ratio is 22.47. Camurus AB's value of 38.98 is 73.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.47, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current Forward PE Ratio of 38.98 is 73.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current Forward PE Ratio is 38.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $73.90, compared to a current price of $61.01 — trading 17.4% below its estimated fair value. The current Forward PE Ratio is 38.98 and 73.5% above the Biotechnology industry median of 22.47. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Camurus AB (CAMRF), the current Forward PE Ratio is 38.98 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $61.01 is trading 17.4% below its estimated GF Value™ of $73.90.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
Forward PE Ratio: 38.98
GF Value™: $73.90 vs. price of $61.01 (17.4% below fair value)
Industry Position: 73.5% above the Biotechnology median (#235 of 355)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 